Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield, Sheffield S10 2HQ, U.K.
Institute of Biochemistry, Life Science Building, National Chung-Hsing University, Taichung City 402, Taiwan.
Biochem Soc Trans. 2021 Apr 30;49(2):775-792. doi: 10.1042/BST20200690.
Repeat-associated non-AUG (RAN) translation was discovered in 2011 in spinocerebellar ataxia type 8 (SCA8) and myotonic dystrophy type 1 (DM1). This non-canonical form of translation occurs in all reading frames from both coding and non-coding regions of sense and antisense transcripts carrying expansions of trinucleotide to hexanucleotide repeat sequences. RAN translation has since been reported in 7 of the 53 known microsatellite expansion disorders which mainly present with neurodegenerative features. RAN translation leads to the biosynthesis of low-complexity polymeric repeat proteins with aggregating and cytotoxic properties. However, the molecular mechanisms and protein factors involved in assembling functional ribosomes in absence of canonical AUG start codons remain poorly characterised while secondary repeat RNA structures play key roles in initiating RAN translation. Here, we briefly review the repeat expansion disorders, their complex pathogenesis and the mechanisms of physiological translation initiation together with the known factors involved in RAN translation. Finally, we discuss research challenges surrounding the understanding of pathogenesis and future directions that may provide opportunities for the development of novel therapeutic approaches for this group of incurable neurodegenerative diseases.
重复相关的非 AUG(RAN)翻译于 2011 年在脊髓小脑共济失调 8 型(SCA8)和强直性肌营养不良 1 型(DM1)中被发现。这种非典型的翻译形式发生在所有阅读框架中,包括编码区和非编码区的 sense 和 antisense 转录本,它们携带三核苷酸到六核苷酸重复序列的扩展。自那以后,RAN 翻译在已知的 53 种微卫星扩展疾病中的 7 种中被报道,这些疾病主要表现为神经退行性特征。RAN 翻译导致低复杂度聚合重复蛋白的生物合成,具有聚集和细胞毒性特性。然而,在缺乏典型 AUG 起始密码子的情况下组装功能性核糖体所涉及的分子机制和蛋白质因子仍未得到很好的描述,而二级重复 RNA 结构在启动 RAN 翻译中起着关键作用。在这里,我们简要回顾了重复扩展障碍、其复杂的发病机制以及生理翻译起始的机制,以及已知参与 RAN 翻译的因素。最后,我们讨论了围绕发病机制理解和未来方向的研究挑战,这些可能为这组无法治愈的神经退行性疾病的新型治疗方法的发展提供机会。